Nucleoside drug transporter polymorphisms play a significant role in patient responses to drugs. The aim was to investigate the effect of multi-drug resistance protein 4, multi-drug resistance protein 5 and human concentrative nucleoside transporter 1 gene polymorphisms on the response to entecavir treatment in chronic hepatitis B patients.
Methods
A total of 324 chronic HBV treatment-naive Chinese Han patients treated with entecavir 0.5 mg daily for 1 year were enrolled. Patients were divided into a response group and non-response group according to the decline of HBV DNA levels. A multiplex SNaPshot single-base extension method was designed for genotyping.
Results
The rs3751333GG genotype of multi-drug resistance protein 4 was significantly different between the response group and non-response group at 6 and 12 months (P=0.005 and P=0.019, respectively). Multivariate analysis showed that the rs37751333GG genotype was significantly associated with responses at 6 and 12 months (odds ratio 2.630, 95% CI 1.391, 4.974, P=0.003; odds ratio 2.968, 95% CI 1.416, 6.221, P=0.004).
Conclusions
The multi-drug resistance protein 4 variant was significantly associated with HBV DNA level suppression in chronic hepatitis B patients treated with entecavir, and therefore, patients with the rs3751333GG genotype might respond better to entecavir in the Chinese Han population.
References
1.
European Association For The Study Of The Liver.EASL clinical practice guidelines: management of chronic hepatitis B virus infection.J Hepatol2012; 57: 167–185.
FungJ., LaiC.L., SetoW.K., YuenM F.Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B.J Antimicrob Chemother2011; 66: 2715–2725.
4.
OzarasR., KhodorH., YetimN.Monotherapy for hepatitis B infection: a review of treatment options.Expert Rev Anti Infect Ther2015; 13: 1457–1468.
5.
GrossmanI.ADME pharmacogenetics: current practices and future outlook.Expert Opin Drug Metab Toxicol2009; 5: 449–462.
6.
Errasti-MurugarrenE., Pastor-AngladaM.Drug transporter pharmacogenetics in nucleoside-based therapies.Pharmacogenomics2010; 11: 809–841.
7.
BorstP., de WolfC., van de WeteringK.Multidrug resistance-associated proteins 3, 4, and 5.Pflugers Arch2007; 453: 661–673.
8.
NakagawaH., ToyodaY., Wakabayashi-NakaoK., TamakiH., OsumiM., IshikawaT.Ubiquitin-mediated proteasomal degradation of ABC transporters: a new aspect of genetic polymorphisms and clinical impacts.J Pharm Sci2011; 100: 3602–3619.
9.
JankeD., MehralivandS., StrandD.6-mercaptopurine and 9- (2- phosphonyl-methoxyethyl) adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC5.Hum Mutat2008; 29: 659–669.
10.
AndersonP.L., LambaJ., AquilanteC.L., SchuetzE., FletcherC V.Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study.J Acquir Immune Defic Syndr2006; 42: 441–449.
11.
WijnholdsJ., MolC.A., van DeemterL.Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs.Proc Natl Acad Sci U S A2000; 97: 7476–7481.
12.
SmithK.M., NgA.M., YaoS.Y.Electrophysiological characterization of a recombinant human Na+-coupled nucleoside transporter (hCNT1) produced in Xenopus oocytes.J Physiol2004; 558: 807–823.
13.
WooH.I., KimK.K., ChoiH.Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine.Pharmacogenomics2012; 13: 1023–1035.
14.
KisO., RobillardK., ChanG.N., BendayanR.The complexities of antiretroviral drug-drug interactions: role of ABC and SLC transporters.Trends Pharmacol Sci2010; 31: 22–35.
15.
ShiY.Y., HeL.SHEsis, a powerful platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci.Cell Res2005; 15: 97–98.
16.
GradhandU., LangT., SchaeffelerE.Variability in human hepatic MRP4 expression: influence of cholestasis and genotype.Pharmacogenomics J2008; 8: 42–52.
BanH., AndohA., ImaedaH.The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease.J Gastroenterol2010; 45: 1014–1021.
19.
RiusM., NiesA.T., Hummel-EisenbeissJ., JedlitschkyG., KepplerD.Cotransport of reduced glutathione with bile salts by MRP4 (ABCC5) localized to the basolateral hepatocyte membrane.Hepatology2003; 38: 374–384.
20.
van AubelR.A., SmeetsP.H., PetersJ.G., BindelsR.J., RusselF.G.The MRP4/ABCC5 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP.J Am Soc Nephrol2002; 13: 595–603.
21.
JedlitschkyG., TirschmannK., LubenowL.E.The nucleotide transporter MRP4 (ABCC5) is highly expressed in human platelets and present in dense granules, indicating a role in mediator storage.Blood2004; 104: 3603–3610.
22.
ZelcerN., ReidG., WielingaP.Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4).Biochem J2003; 371: 361–367.
23.
KönigJ., HartelM., NiesA.T.Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma.Int J Cancer2005; 115: 359–367.
24.
MennoneA., SorokaC.J., CaiS.Y.Mrp4-/- mice have an impaired cytoprotective response in obstructive cholestasis.Hepatology2006; 43: 1013–1021.
25.
ZollnerG., WagnerM., FickertP.Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis.Liver Int2007; 27: 920–929.
26.
Di MartinoM.T., ArbitrioM., LeoneE.Single nucleotide polymorphisms of ABCC5 and ABCG1 transporter genes correlate to irinotecan-associated gastrointestinal toxicity in colorectal cancer patients: a DMET microarray profiling study.Cancer Biol Ther2011; 12: 780–787.
27.
KwanP., WongV., NgP.W.Gene-wide tagging study of the association between ABCC2, ABCC5 and ABCG2 genetic polymorphisms and multidrug resistance in epilepsy.Pharmacogenomics2011; 12: 319–325.
28.
KoolM., de HaasM., SchefferG.L.Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines.Cancer Res1997; 57: 3537–3547.
29.
SooR.A., WangL.Z., NgS.S.Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients.Lung Cancer2009; 63: 121–127.
30.
Tekola-AyeleF., AdeyemoA., AseffaA.Clinical and pharmacogenomic implications of genetic variation in a Southern Ethiopian population.Pharmacogenomics J2015; 15: 101–108.
